1)Defination of all as per Insurance Guidelines and policy Terms and conditions. 2)Need to thorough about all exclusion. 3)Need to know about changes as per new guidelines of IC. 4)All about Angioplasty,stent . 5)what u know about Auditing and it's types? 6) Cancer and anti-cancer drugs.

Question

Accepted Answer

Intervention: Clinical and Economic Impact of Standard Versus Extended Duration Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration [Internet]. Show details Contents Search term < PrevNext > Appendix 8Inclusion and Exclusion Criteria for Included Studies Table 43Major Inclusion and Exclusion Criteria of Included Randomized Controlled Trials RCT Major Inclusion Criteria Major Exclusion Criteria PRODIGY24 Chronic, stable coronary artery disease or ACS including non-STEMI and STEMI with at least one lesion with a diameter stenosis of ≥ 50% and with a reference vessel diameter of ≥ 2.25 mm Known allergy to ASA or clopidogrel, history of bleeding diathesis, active bleeding or previous stroke in the past six months, concomitant need of oral anticoagulant therapy, scheduled elective surgery within 24 months of PCI, major surgery within 15 days DES-LATE26 All candidates for DAPT after DES implantation who had not had a major adverse cardiovascular event or major bleeding for 12 months after PCI Life expectancy < 1 year, concomitant vascular disease that required the long-term use of clopidogrel or other established indications for clopidogrel therapy ARCTIC-Interruption33 Planned DES implantation Primary PCI for STEMI, planned use of GPIIb/IIIa inhibitors, chronic anticoagulation treatment, or bleeding diathesis ITALIC30 Candidates pre-treated with DAPT after implanted, with at least 1 XIENCE V DES Primary PCI for acute MI and treatment of the left main artery, non-responders to ASA resistance test, prior DES implantation within 1 year, oral anticoagulation therapy or abciximab treatment during hospital stay, scheduled elective surgery within 12 months, known hemorrhagic diathesis DAPT23 All candidates for DAPT after treatment with FDA-approved DES or BMS who had not had a major adverse cardiovascular or cerebrovascular event, repeat revascularization, or moderate or severe bleeding 12 months after PCI Use of stent with diameter of < 2.25 mm or > 4.0 mm, scheduled elective surgery within 30 months, concomitant need of oral anticoagulant therapy, patient treated with both DES and BMS, a life expectancy of < 3 years OPTIDUAL29 Symptoms of stable angina, silent ischemia, or ACS with ≥ 1 lesion, with stenosis of > 50% located in a native vessel ≥ 2.25 mm in diameter and implanted with ≥ 1 DES or BMS and treated with clopidogrel plus ASA for 12 months Requirement for oral anticoagulant, DES implantation in an unprotected left main coronary artery, malignancy or other coexisting conditions associated with life expectancy of < 2 years, other revascularization with a DES within 9 months or a BMS within 4 weeks prior to this study NIPPON22 “Optimal indication for percutaneous coronary intervention” and no known contraindications to dual antiplatelet therapy, including patients with acute MI Cardiogenic shock at the time of PCI, concomitant disease for which a thienopyridine was essential for treatment, history of stent thrombosis, ejection fraction of < 30%, life expectancy of < 1year, active bleeding condition, planned surgery necessitating discontinuation of antiplatelet therapy (> 14 days) within 18 months, index stent procedure for a saphenous vein graft, in-stent re-stenosis of DES, or unprotected LMT lesion; history of intracranial bleeding or ischemic stroke within 6 months before enrolment; DES for another lesion within 6 months prior to index PCI Dadjou et. al (2016)31 Patients with stenosis of more than 70% in any coronary vessel, with a reference diameter of more than 2.25 that was suitable for coronary stenting Planned surgery within 6 months of PCI unless the DAPT could be continued throughout the perioperative period, history of bleeding diathesis, major surgery within 15 days, active bleeding, previous hemorrhagic stroke in the past 6 months that contraindicated the use of DAT, pregnancy, life expectancy of < 24 months.

1)Defination of all as per Insurance Guidelines and policy Terms and conditions. 2)Need to thorough about all exclusion. 3)Need to know about changes as per new guidelines of IC. 4)All about Angioplasty,stent . 5)what u know about Auditing and it's types? 6) Cancer and anti-cancer drugs.

Top Medi Assist India Medical Officer interview questions & answers

Popular interview questions of Medical Officer

Top HR questions asked in Medi Assist India Medical Officer